The FDA has granted accelerated approval to Novo Nordisk’s Wegovy (semaglutide) for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis. This decision is based on Phase 3 data from the ESSENCE trial, where the drug significantly outperformed placebo in resolving liver inflammation and improving scarring. Wegovy is now the first GLP-1 receptor agonist approved for this liver condition.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.